Tumor response to immunochemotherapy may spare some head and neck cancer patients radical surgery

Patients with locally precocious caput and cervix squamous compartment carcinoma (HNSCC) whose tumors responded to neoadjuvant immunochemotherapy (ICT) and who underwent little extended country had precocious disease-free endurance and organ preservation rates, according to a survey published successful Clinical Cancer Research, authored by Kunyu Yang, MD, manager of Union Hospital Cancer Center astatine Tongji Medical College and Huazhong University of Science and Technology successful China, and others.